Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2662
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSanmamed, Miguel F-
dc.contributor.authorEsteban, E-
dc.contributor.authorUriol, E-
dc.contributor.authorZarate, R-
dc.contributor.authorCapelan, M-
dc.contributor.authorMuriel, C-
dc.contributor.authorCrespo, G-
dc.contributor.authorBerros, J P-
dc.contributor.authorPardo-Coto, P-
dc.contributor.authorPerez, Q-
dc.contributor.authorAlvarez-Fernández, C-
dc.contributor.authorJiménez Fonseca, P-
dc.contributor.authorLuque, M-
dc.contributor.authorAstudillo, A-
dc.date.accessioned2017-05-26T09:34:48Z-
dc.date.available2017-05-26T09:34:48Z-
dc.date.issued2017-03-20-
dc.identifier.citationSanmamed MF, Esteban E, Uriol E, Zarate R, Capelan M, Muriel C, et al. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours. J Transl Med. 2017; 15(1):62.es_ES
dc.identifier.issn1479-5876 (Online)es_ES
dc.identifier.otherPMC5358043es_ES
dc.identifier.urihttp://hdl.handle.net/10668/2662-
dc.description.abstractBackground Inguinal orchiectomy is curative in 70–80% of clinical stage I testicular germ cell tumours (CS I TGCT). The identification of patients who are at low risk of relapse is critical to avoid unnecessary treatment. The aim of this study is to explore EGFR, hMLH-1/hMSH-2 and microsatellite instability (MSI) as potential prognostic factors of recurrence in CS I TGCT. Methods Fifty-six CS I TGCT patients who underwent inguinal orchiectomy were included in this study. We analysed the relationship between clinicopathological and molecular factors with survival. Analysis of hMLH1, hMSH2 and EGFR expression was carried out by immunohistochemistry. Methylation status of the hMLH1 promoter was determined by pyrosequencing analysis in selected cases. EGFR exons 19, 20, 21 were analysed by PCR labeled-fragments and MSI status was determined using standard Multiplex MSI assays. Results Classical pathological factors such as lymphovascular invasion, high percentage of embryonal carcinoma, rete testis invasion or tumour size ≥4 cm showed a significant relationship with a higher risk of relapse. Additionally, it was found that an epididymis invasion proved to be a significant independent poor prognostic factor of recurrence (p = 0.001). hMLH1 or hMSH2 expression showed no significant association with risk of relapse and no MSI was found. EGFR expression was observed in 30.4% of samples and its expression was associated with higher risk of relapse (HR 3.5; 95% CI 1.3–9.8; p = 0.016). None of the cases presented EGFR kinase domain mutations. Conclusions Epididymis invasion and EGFR expression, but not hMLH-1/hMSH-2 or MSI, could be potentially useful as new prognostic factors of recurrence for CS I TGCT.es_ES
dc.description.sponsorshipThis work was supported by “Fundación para el Desarrollo de la Oncología (FUNDESO)”.es_ES
dc.language.isoenes_ES
dc.publisherBiomed Centrales_ES
dc.relation.ispartofJournal of Translational Medicinees_ES
dc.subjectTesticular germ cell tumoures_ES
dc.subjectEGFRes_ES
dc.subjectEpididymis invarsiones_ES
dc.subjecthMSH-2es_ES
dc.subjectMSIes_ES
dc.subjectCarcinoma embrionarioes_ES
dc.subjectEpidídimoes_ES
dc.subjectExoneses_ES
dc.subjectHumanoses_ES
dc.subjectInmunohistoquímicaes_ES
dc.subjectMasculinoes_ES
dc.subjectMetilaciónes_ES
dc.subjectInestabilidad de microsatéliteses_ES
dc.subjectRecurrencia local de neoplasiaes_ES
dc.subjectOrquiectomíaes_ES
dc.subjectPronósticoes_ES
dc.subjectRecurrencees_ES
dc.subjectRed Testiculares_ES
dc.subjectNeoplasias Testiculareses_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Carcinoma, Embryonales_ES
dc.subject.meshMedical Subject Headings::Anatomy::Urogenital System::Genitalia::Genitalia, Male::Epididymises_ES
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Gene Components::Exonses_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Histological Techniques::Histocytochemistry::Immunohistochemistryes_ES
dc.subject.meshMedical Subject Headings::Check Tags::Malees_ES
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Chemical Phenomena::Chemical Processes::Biochemical Processes::Alkylation::Methylationes_ES
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Genomic Instability::Microsatellite Instabilityes_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplastic Processes::Neoplasm Recurrence, Locales_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonales_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Urogenital Surgical Procedures::Urologic Surgical Procedures::Urologic Surgical Procedures, Male::Orchiectomyes_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosises_ES
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrencees_ES
dc.subject.meshMedical Subject Headings::Anatomy::Urogenital System::Genitalia::Genitalia, Male::Testis::Rete Testises_ES
dc.subject.meshMedical Subject Headings::Diseases::Male Urogenital Diseases::Urogenital Neoplasms::Genital Neoplasms, Male::Testicular Neoplasmses_ES
dc.titleEpidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumourses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.versionYeses_ES
dc.identifier.pmid28320414es_ES
dc.rights.accessRightsAcceso abiertoes_ES
dc.identifier.doi10.1186/s12967-017-1162-3es_ES
dc.type.versioninfo:eu-repo/semantics/publishedes_ES
dc.relation.publisherversionhttps://translational-medicine.biomedcentral.com/articles/10.1186/s12967-017-1162-3#Abs1es_ES
dc.contributor.authoraffiliation[Sanmamed,MF] Department of Immunobiology, School of Medicine, Yale University, New Haven, USA. [Sanmamed,MF; Estebam.E: Iropñ.E: Berrps.K^: Perez,Q; Alvarez-Fernández,C; Jiménez Fonseca,P; Luque,M] Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain. [Zarate,R] Clinical Genetics Unit, Clínica Universidad de Navarra, Pamplona, Spain. [Capelan,M] Breast Unit, Royal Marsden NHS Foundation Trust, London, UK. [Muriel,C] Department of Medical Oncology, Hospital Regional Universitario Carlos Haya, Málaga, Spain. [Crespo,G] Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain. [Pardo-Coto,P] Department of Medical Oncology, Centro Médico de Asturias, Oviedo, Spain. [Astudillo,A] Department of Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain.es_ES
Appears in Collections:01- Artículos - Hospital Regional de Málaga

Files in This Item:
File Description SizeFormat 
SanmamedMF_EpidermalGrowth.pdfArtículo publicado1,62 MBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons